NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC

April 22, 2015

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for February 4, 2015 meeting (pages 3-8; Tab1)

IV. Secretary’s report (page 9; Tab 2)

V. Old Business (Tab 3)
   A. Proposed protocol for the safe and efficient use of opioids in acute pain (page 11)
   B. HMO (UHC) response to DURB follow-up questions regarding protocols (page 12)

VI. New Business
   A. Sofosbuvir/ledipasvir (Harvoni®) proposed protocol (pages 13-16; Tab 4)
   B. Ombitasvir, paritaprevir, ritonavir and dasabuvir (Viekira®) proposed protocol (pages 17-28; Tab 5)
   C. Protocols review (pages 29-44; Tab 6)
      1. Erythropoietin Stimulating Agents (ESA)
      2. Repository corticotropin (H.P. Acthar Gel®)

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items (pages 47-48; Tab 8)
    3. DHS and DHSS Programs Top Drugs Report (pages 49-60; Tab 9)
    4. Medication information: (pages 61-64; Tab 10)
       (a) FDA approves Evotaz® for HIV treatment
       (b) FDA approves Prezcofax® for HIV treatment
       (c) Antipsychotic overuse not just a problem in nursing homes
       (d) FDA: Testosterone Labels Must Note CV, Stroke Risks